Immune cells armed with antibodies take on pancreatic cancer
NCT ID NCT04137536
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-phase study tests a new treatment called EGFR-BATs for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are trained in a lab to better attack cancer cells. The main goal is to find the safest dose and understand any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University of Virginia (Specimen Analysis)
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.